Want to see NEPH full AI Analyst Report?
NEPH Stock Chart & Stats
$3.64
-$0.22(-6.04%)
At close: 4:00 PM EDT
$3.64
-$0.22(-6.04%)
Day’s Range― - ―
52-Week Range$2.66 - $6.42
Previous Close$1.57
Volume3.78K
Average Volume (3M)75.62K
Market Cap
$50.93M
Enterprise Value$35.85
Total Cash (Recent Filing)$4.70M
Total Debt (Recent Filing)$872.00K
Price to Earnings (P/E)28.8
Beta-0.31
Next Earnings
Nov 05, 2026EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.16
Shares Outstanding10,860,120
10 Day Avg. Volume107,933
30 Day Avg. Volume75,620
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)5.08
Price to Sales (P/S)2.76
P/FCF Ratio31.48
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$6.38Price Target Upside75.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.09
Revenue Forecast (FY)$21.37M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetLow leverage and a cash cushion provide durable financial flexibility, enabling continued investment in product development, regional expansion and working-capital needs without forcing dilutive financing. This reduces solvency risk and supports execution of multi-quarter growth initiatives.
High And Improving Gross MarginsSustained ~60% gross margins reflect a differentiated product and pricing mix that supports profitability across cycles. Margin expansion versus prior years signals improving cost structure and product economics that can fund R&D, service expansion, and installed-base growth over the next several quarters.
Recurring Programmatic & Service RevenueGrowth in programmatic product sales and accelerating service revenue deepen customer relationships and create recurring aftermarket demand. The razor-and-blades installed-base model supports predictable repeat consumable sales and services revenues that bolster long-term revenue visibility.
Bears Say
Weak Cash ConversionEarnings are not translating into cash due to working-capital swings, increasing inventory and receivables. Persistent negative cash conversion can strain funding for growth, force external financing or slow product rollout, making operational gains less durable without improvement.
Ongoing Margin HeadwindsStructural cost pressures—tariffs, adverse FX and rising freight—can erode reported gross margins despite strong product economics. If sustained, these headwinds compress operating leverage, reduce reinvestment capacity and make recent margin improvements harder to maintain over several quarters.
Limited New Customer Adds; Product Adoption EarlyGrowth has relied more on deeper penetration at existing sites than new-account wins, and new PFAS/microplastics offerings remain early-stage. Slower new-customer acquisition and delayed product diversification raise execution risk and could limit sustainable top-line expansion.
NEPH FAQ
What was Nephros Inc’s price range in the past 12 months?
Nephros Inc lowest stock price was $2.66 and its highest was $6.42 in the past 12 months.
What is Nephros Inc’s market cap?
Nephros Inc’s market cap is $50.93M.
When is Nephros Inc’s upcoming earnings report date?
Nephros Inc’s upcoming earnings report date is Nov 05, 2026 which is in 82 days.
How were Nephros Inc’s earnings last quarter?
Nephros Inc released its earnings results on Aug 06, 2026. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.003 by $0.107.
Is Nephros Inc overvalued?
According to Wall Street analysts Nephros Inc’s price is currently Undervalued.
Does Nephros Inc pay dividends?
Nephros Inc does not currently pay dividends.
What is Nephros Inc’s EPS estimate?
Nephros Inc’s EPS estimate is 0.03.
How many shares outstanding does Nephros Inc have?
Nephros Inc has 10,860,120 shares outstanding.
What happened to Nephros Inc’s price movement after its last earnings report?
Nephros Inc reported an EPS of $0.11 in its last earnings report, beating expectations of $0.003. Following the earnings report the stock price went up 17.27%.
Which hedge fund is a major shareholder of Nephros Inc?
Currently, no hedge funds are holding shares in NEPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nephros Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.38 (75.14% Upside)
$6.38 (75.14% Upside)
Hedge Fund Trend
Decreased
By 11.5K Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
226.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
28.81%
Trailing 12-Months
Company Description
Nephros Inc
Nephros, Inc. is a company that specializes in developing and marketing sophisticated water purification solutions across the United States, catering to both the medical and commercial sectors. Its operations are structured into three primary segments: Water Filtration, Pathogen Detection, and Renal Products. Within its Water Filtration division, Nephros offers advanced ultrafiltration products. These are vital in dialysis centers for eradicating biological contaminants from water and bicarbonate concentrate, and are also deployed in hospitals to prevent infections from waterborne pathogens such as Legionella and Pseudomonas. Their utility extends to military installations, outdoor recreation, commercial establishments, and various other healthcare facilities. The Pathogen Detection segment focuses on developing and distributing real-time water testing systems, which deliver critical, actionable data regarding waterborne pathogens. Furthermore, under its Renal Products segment, the company provides medical devices designed for individuals suffering from renal disease, notably including a second-generation hemodiafiltration system tailored for patients with end-stage renal disease. Additionally, Nephros markets a range of water filters under the Nephros and AETHER brands. These filters are engineered not only to enhance water taste and eliminate odors but also to significantly reduce biofilm, bacteria, and scale accumulation in downstream equipment, serving the food service, hospitality, convenience store, and healthcare industries. Established in 1997, Nephros, Inc. maintains its corporate headquarters in South Orange, New Jersey.
NEPH Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational and financial progress: record quarterly revenue, robust programmatic and service growth, and significant improvements in net income and adjusted EBITDA. These positives were tempered by margin items—partly benefited by a one-time $600K tariff refund—and by cash flow pressures driven by rising inventory and receivables, ongoing tariff/FX/freight cost headwinds, and early-stage adoption of new products. Management emphasized durable, broad-based execution, ongoing investments in markets, services and education, and confidence in future growth, while acknowledging margin and cash conversion areas for improvement.View all NEPH earnings summariesNEPH Stock 12 Month Forecast
Average Price Target
$6.38
▲(75.14% Upside)
Technical Analysis
Ownership Overview
4.83% Insiders
2.38% Mutual Funds
42.12% Other Institutional Investors
48.60% Public Companies and
Individual Investors









